Abstract: Disclosed is an invention relating to a novel lymphokine and to the production and uses thereof. The invention also relates to a monoclonal antibody specific to the lymphokine and its production. The novel lymphokine is a glycoprotein having a molecular weight of 20,000.+-.2,000 daltons; isoelectric point pI, 5.6.+-.0.2; electrophoretic mobility Rf, 0.29.+-.0.02; and cytotoxic on a mouse cell line L 929. The lymphokine inhibits significantly the growth of malignant human tumors in vivo. The monoclonal antibody is IgM or IgG class, and neutralizes specifically the cytotoxic activity of the lymphokine.

Abstract: This invention has made it possible to uniformly gelatinize and disperse a highly concentrated starch slurry of a concentration as high as 10% or more by gelatinizing at an elevated temperature; hitherto it was considered next to impossible to uniformly gelatinize and disperse such highly concentrated starch slurries, and, according to the present invention, the upper limit of saccharification of the starch slurry is increased by selectively decomposing the .alpha.-1,6-glucoside bonds in the starch by means of an .alpha.-1,6-glucosidase and, thereby, to make it possible to obtain a highly pure maltose.